Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Wilms tumor (WT) is an embryonic kidney cancer, for which histone acetylation might be a therapeutic target. LBH589, a novel targeted agent, suppresses histone deacetylases in many tumors. This study investigated the antitumor activity of LBH589 in SK-NEP-1 and G401 cells.SK-NEP-1 and G401 cell grow...
Main Authors: | Tao Yan-Fang, Li Zhi-Heng, Xu Li-Xiao, Fang Fang, Lu Jun, Li Gang, Cao Lan, Wang Na-Na, Du Xiao-Juan, Sun Li-Chao, Zhao Wen-Li, Xiao Pei-Fang, Zhao He, Su Guang-Hao, Li Yan-Hong, Li Yi-Ping, Xu Yun-Yun, Zhou Hui-Ting, Wu Yi, Jin Mei-Fang, Liu Lin, Ni Jian, Hu Shao-Yan, Zhu Xue-Ming, Feng Xing, Wang Jian, Pan Jian |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4503685?pdf=render |
Similar Items
-
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
by: Jan M Klein, et al.
Published: (2013-01-01) -
Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.
by: Weiwei Xiao, et al.
Published: (2013-01-01) -
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
by: Nageatte Ibrahim, et al.
Published: (2016-11-01) -
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
by: Ioanna Savvidou, et al.
Published: (2022-02-01) -
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
by: Lenz Heinz-Josef, et al.
Published: (2009-11-01)